A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will evaluate the efficacy and safety of oseltamivir in the seasonal
prophylaxis of influenza in immunocompromised participants (as represented by transplant
recipients). Transplant recipients enrolled when influenza is circulating in the community
will be randomized to receive oseltamivir syrup or capsules 30 milligrams (mg) to 75 mg daily
(depending on body weight) or placebo for 12 weeks. Influenza symptoms and safety data will
be recorded throughout the study.